Home / Auditor changes / Avidity Biosciences, Inc.

3/5Avidity Biosciences, Inc. (RNA): Auditor change

Filed 2025-04-29 路 Form 8-K 路 Accession 0001599901-25-000091 micro

Market data

Price before filing: n/a (n/a close, split/dividend-adjusted)
Market cap at flag: n/a 路 Latest: $131.2M (2026-10-16)

What happened next

WindowRNASPYvs SPY
30 daysn/an/an/a
90 daysn/an/an/a
180 daysn/an/an/a

Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.

Verified excerpt

"As a result of this process, on April 25, 2025, the Audit Committee approved the appointment of Deloitte & Touche LLP ("Deloitte") as the Company's independent registered public accounting firm for the year ending December 31, 2025, with such appointment to be effective immediately following the filing of the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2025 (the "Q1 Form 10-Q")."

Quoted from the filing. Source

What this means

The company changed its outside auditor (8-K Item 4.01). A dismissal or resignation, especially near an annual report or with reported disagreements, is a warning sign. Changes caused by audit firms merging are usually routine.

Type: dismissed
Disagreements reported: no

Read the original filing on SEC.gov →

Not investment advice. Automated summary; verify against the filing.

Get the weekly "Red Flags" newsletter

The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.

Newsletter delivered by beehiiv. See our privacy policy.